Lab Automation In-Depth Focus 2020
In this in-depth focus are features on the best data management options currently available and how the future of drug discovery will be connected and fully automated.
List view / Grid view
In this in-depth focus are features on the best data management options currently available and how the future of drug discovery will be connected and fully automated.
Gilson interviews Steve DeCabooter, Director of Product Information Platforms, about the growing role of connected tools and systems in the lab.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
Drug Target Review has created a COVID-19 research hub with forum space for discussions and a place to share your research - plus all of our articles and news.
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
Seamlessly track, record, and share your protocol and results with Gilson’s TRACKMAN® Connected and the SciNote digital lab notebook.
Researchers have used high-throughput screening on AAV vector capsid libraries to identify which ones are best for certain gene therapies.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
A new Cas13 RNA screen has been used to establish guide RNAs for the COVID-19 coronavirus and human RNA segments which could be used in vaccines, therapeutics and diagnostics.
Multiple co-signalling molecules regulate T cell activation.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
TRACKMAN® Connected and PIPETMAN® M Connected allow researchers to pipette reliably and consistently while tracking protocol and protecting data.